Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis

Overview

Pneumococcal meningitis is an infection of the membrane that covers the brain. It is a serious infection which is currently treated with a combination of corticosteroids (dexamethasone) and 3rd generation cephalosporins. Nevertheless, complications associated with meningitis are relatively frequent and severe. Recent animal studies have shown that another antibiotic, daptomycin, can reduce the mortality and long-term effects of pneumococcal meningitis. Daptomycin is widely used worldwide in humans for other diseases, with few side effects. This study aims to evaluate the effect of daptomycin on the proliferation of the bacterial infection, and therefore on inflammation. Daptomycin will be added to the currently recommended treatment with the same dosage used for other diseases. Roughly 130 patients with suspected pneumococcal meningitis admitted to the emergency departments of hospitals throughout France will be asked to participate in this study. The participation period will last approximately 3 months.

Full Title of Study: “Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis: AddaMAP Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2024

Interventions

  • Drug: Daptomycin
    • Daptomycin will be given by intravenous infusion and administered over a 30 minutes infusion, daily, for 8 days and at the dosis of 10mg/kg/day.

Arms, Groups and Cohorts

  • Experimental: Patients

Clinical Trial Outcome Measures

Primary Measures

  • Disability-free survival, assessed with the modified Rankin Scale (mRS)
    • Time Frame: At Day 30

Secondary Measures

  • Overall mortality
    • Time Frame: At Day 30 and Day 90
  • Disability level assessed with the mRS in surviving patients
    • Time Frame: At Day 30 and Day 90
  • Disability level assessed with the Glascow Coma Scale and the Glasgow Outcome Scale in the overall efficacy population
    • Time Frame: At Day 30 and Day 90
  • Disability level assessed with mini-mental score in surviving patients
    • Time Frame: At Day 30 and Day 90
  • Hearing loss assessed with the Hearing Handicap Inventory test
    • Time Frame: At Day 30 and Day 90
  • Hearing loss assessed with audiometry
    • Time Frame: At Day 30
  • Hearing loss assessed with the Hearing-it test
    • Time Frame: At Day 30
  • Quality of life assessed with the 12-Item Short Form Health Survey (SF-12)
    • Time Frame: At Day 30 and Day 90
    • Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning
  • Quality of life assessed with WHO QOL BREF
    • Time Frame: At Day 30 and Day 90
  • Number of days without hospitalisation (including ICU)
    • Time Frame: At Day 30 and Day 90
  • Number of days without antimicrobial therapy
    • Time Frame: At Day 30
  • Frequency and type of side effects related to daptomycine
    • Time Frame: Within 30 days after daptomycin start

Participating in This Clinical Trial

Inclusion Criteria

  • Persons aged over 18 years – With Suspected pneumococcal meningitis : – clinical presentation evocative of pneumococcal meningitis : acute onset of ,meningeal signs, history of cranial trauma or fistula, knowledge of alteration of humoral immunity,, asplenia, alcoholism with/or – clearly purulent CSF with/ or, – presence of diplococcus on the Gram stain of CSF or positive pneumococcal antigen in the CSF, or polymorphonuclear cells in CSF > 100 – Written consent or inclusion in an emergency – Affiliation to a social security system Exclusion Criteria:

  • Contraindication to cephalosporin – Immediate and severe hypersensitivity to β-lactam antimicrobial – Contraindication to dexamethasone – Contraindication to daptomycin – Previous exposition to daptomycin (within one year) – Women who are able to procreate without effective contraception and pregnant or breastfeeding women – Patients under ward of court – Refusal at any time after acceptation of the study from the patient or her/his legal representative.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire Dijon
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Pascal CHAVANET, MD, 03 80 29 33 05, pascal.chavanet@chu-dijon.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.